They would only PR subgroups if the entire patient population didn't show positive results. Those numbers being fairly close to p=.05 and the population size leads me to believe not stat sig overall. Even with that you'll see investors not realizing that and there should be a significant pop unless word gets out. But I wouldn't expect it to hold.

At least Cytodyn said they missed the primary endpoint instead of faking it.